03Feb

FDA Halts REGN475 Study

In CategoryArthritis, Bone Health, Muscles, Etc, Drugs and Drug Companies, Osteoporosis
ByRuss Bianchi

The Food and Drug Administration placed studies of Regeneron Pharmaceuticals Inc. and Sanofi-Aventis’ potential osteoarthritis drug on hold because of potential harm to patients’ bones.

FDA Halts REGN475 Study

Share

Tags: , , ,

Comments are closed.